PETE O'HEERON - 24 Jan 2024 Form 3/A Insider Report for FibroBiologics, Inc. (FBLG)

Role
Chief Executive Officer, Director
Signature
/s/ Ruben A. Garcia, by Power of Attorney
Issuer symbol
FBLG
Transactions as of
24 Jan 2024
Net transactions value
$0
Form type
3/A
Filing time
12 Aug 2024, 21:58:09 UTC
Date Of Original Report
08 Feb 2024
Previous filing
24 Jan 2024
Next filing
10 Jul 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding FBLG Series C Preferred Stock 24 Jan 2024 Common Stock 2,500 $0.000000 Direct F1
holding FBLG Stock Option (Right to Buy) 24 Jan 2024 Common Stock 1,853,000 $2.28 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series C Preferred Stock is convertible into the issuer's Common Stock on a 1-for-1 basis and has no expiration date. Upon the closing of the issuer's direct listing, the Series C Preferred Stock will convert, without the payment of additional consideration by or to the holder thereof, into the issuer's Common Stock on a 1-for-1 basis upon any transfer of such shares. For as long as they remain outstanding, the Series C Preferred Stock of the issuer held by the Reporting Person are subject to an irrevocable proxy issued by the Reporting Person in favor and for the benefit of the board of directors of the issuer.
F2 1/4 of the options vested on January 1, 2024, with the remainder vesting monthly over 36 months.

Remarks:

This amendment is filed to include stock options in Table II that were inadvertently omitted in the original filing and to report the Series C Preferred Stock in Table II instead of Table I. Exhibit 24 - Power of Attorney